Imlunestrant(Synonyms: LY-3484356)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Imlunestrant (Synonyms: LY-3484356)

Imlunestrant (LY3484356) 是具有口服活性的选择性雌激素受体的降解剂(SERD)。Imlunestrant (LY3484356) 可用以ER+ 和HER2 乳腺癌。

Imlunestrant(Synonyms: LY-3484356)

Imlunestrant Chemical Structure

CAS No. : 2408840-26-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Imlunestrant (LY3484356) is an orally active selective estrogen receptor (ER) degrader (SERD). Imlunestrant (LY3484356) could be used in the study for ER+, HER2-advanced breast cancer[1].

体外研究
(In Vitro)

Imlunestrant (LY3484356) shows favorable efficacy and pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants[1].
Imlunestrant (LY3484356) is a potent degrader and selective pure antagonist of wild type and mutant ERα[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

524.51

Formula

C29H24F4N2O3
CAS 号

2408840-26-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.

    [2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务